Background and Objectives  The recent establishment of the National Healthcare Safety Network Hemovigilance Module in the United States affords an opportunity to compare results with those of other developed nations.

Materials and Methods  Using data from national haemovigilance systems, reactions associated with red blood cell (RBC) transfusion and residual risks of transfusion-transmitted infectious diseases were assembled from 17 nations. Country-specific rates of adverse events were pooled using random-effects Poisson regression.

Results  Febrile non-haemolytic and delayed serologic transfusion reactions were the most frequent adverse events reported after RBC transfusion, occurring in 26 patients per 100,000 RBC units and 25 patients per 100,000 RBC units administered, respectively. Rates of allergic, febrile non-haemolytic and delayed haemolytic transfusion reactions in the United States were significantly greater than the pooled rates from other countries. Frequencies of adverse events generated from the national haemovigilance programme in the United States were considerably lower than when obtained through active surveillance.

Conclusion  Haemovigilance reports of adverse events in the United States are comparable to, or greater than, reports from other developed countries. Rates generated from haemovigilance programmes are lower than those obtained through active surveillance. The lack of universal leucoreduction of RBC units may be a contributing factor to the higher rate of some adverse events in the United States.

Key words: adverse reaction, haemovigilance, international, transfusion.

Introduction  First established in France and Japan in 1993 as a response to the vulnerability of the blood supply after the emergence of HIV [1, 2], haemovigilance systems aim to improve the safety of the blood supply through systematic surveillance of transfusion-related adverse events. Such systems generate recommendations so as to encourage safety throughout the entire process, from blood donation through monitoring of recipients. Several directives from the European Union relate to the regulation, monitoring and safety of blood products, with the haemovigilance component helping to direct member nations' reporting of serious transfusion-related adverse reactions and events [3]. Therefore, haemovigilance systems are widespread in European nations, with prime examples being the United Kingdom with its voluntary Serious Hazards of Transfusion reporting system [99.5% participation in 2013] [4], and the Netherlands with its Transfusion and Transplantation Reactions in Patients haemovigilance programme (98% participation in 2013) [5].

The USA opened its first nationwide haemovigilance system in 2010 as a voluntary module of the National
Healthcare Safety Network [6]. Results from this new system are now available and can be compared with existing haemovigilance programmes. As more nations begin to implement haemovigilance programmes, an assessment of the abilities of national systems to report reactions and a comparative review of event rates can be informative.

Methods

Haemovigilance data on transfusion-related adverse reactions and transfusion-transmitted infections were available from the national haemovigilance systems in each of the following countries: Australia [7], Canada [8], Denmark [9], Finland [10], France [11], Germany [12], Ireland [13], Japan [14–16], the Netherlands [5], New Zealand [17], Norway [18], Portugal [19, 20], Spain [21], Sweden [22], Switzerland [23], United Kingdom[4] and the USA [6]. Data regarding adverse events after RBC transfusion were collected: allergic reactions, anaphylactic reactions, febrile non-haemolytic transfusion reactions (FNHTR), acute and delayed haemolytic transfusion reactions, hypotensive reactions, transfusion-related acute lung injury (TRALI), transfusion-associated dyspnoea, transfusion-associated circulatory overload (TACO), delayed serologic transfusion reactions, post-transfusion purpura and transfusion-transmitted bacterial sepsis. Some countries reported additional categories and these were included as well (acute transfusion-related pain, haemosiderosis). For each country, data from the most recently available report were utilized.

Risks of transfusion-transmitted viruses were available for agents with mandated testing. Reporting methods differ by country, although in the USA, data regarding residual risk of viral transmission were derived from donor testing since long-term follow-up of recipients is not feasible [24]. Because it is theoretically possible that a donor could have newly acquired a virus but is seronegative at the time of the blood donation, seroconversion rates during this infectious window period are used to predict the residual risk of viral infection [24].

Statistical analyses

Rates of non-infectious adverse events were calculated for each country using the number of events (numerator) and the number of RBC units administered (denominator). Rates were reported for each country as events per 100 000 RBC units for non-infectious adverse events and events per million RBC units for infectious adverse events. Canada and Spain were exceptions; adverse events were recorded for components combined (RBCs, platelets, plasma). In the USA, TACO was the only event in which reporting was performed for components combined (RBCs, platelets, plasma). In secondary analyses, adverse event rates from active surveillance in the USA were compared with the rates generated from the passive haemovigilance programme; in these instances, the rates were given using several denominators (per patient, per unit and per transfusion-related hospital stay).

Following current recommendations for summarizing rates [25], random-effects Poisson regression models were generated to pool rates of transfusion-related adverse events with 95% confidence intervals. That is, the numbers of events were fit to a Poisson distribution with the number of RBC units included as an offset. Countries that reported zero events were included and, in such instances, a one-sided exact Poisson 97.5% confidence interval was used for the country-specific rate. Heterogeneity was assessed using a gamma density function (shape parameter = 2, scale = 0.5) for the variance of the random intercept (between-country variance) in the Poisson model. This Rate Index of Heterogeneity (RIH) is unit-independent, encompasses a range from 0% to 100% heterogeneity and is directly derived from the underlying random-effects Poisson model for assessment of rates. Analyses were conducted using Stata/MP 13.1 (College Station, Texas, USA).

Results

Allergic reactions after RBC transfusion occurred in 11 patients per 100 000 RBC units administered (95% CI: 6.55/100 000 to 18.08/100 000) with a RIH of 58.5% (Fig. 1). The rate of allergic reactions in the USA was significantly greater (53.61/100 000; 95% CI: 49.59/100 000–57.87/100 000) than the pooled rate of the other developed countries combined (9.71/100 000; 95% CI: 5.93/100 000–15.85/100 000). Some countries reported anaphylactic reactions separately and these occurred at a lower rate of 0.9 per 100 000 RBC units (RIH = 17.1%). In the United Kingdom, acute transfusion reactions were defined as instances of anaphylaxis or severe allergic reactions, severe febrile reactions, severe hypotensive reactions and severe mixed reactions; these occurred at a rate of nine patients per 100 000 RBC units.

There was variability in the rates of FNHTR across countries (RIH = 94.0%). Overall, the rate was 26 patients per 100 000 RBC units, although the Netherlands, New Zealand and the USA recorded rates in excess of 100 patients per 100 000 RBC units, or approximately one in one-thousand units (Fig. 2). The rate of FNHTR in the USA was significantly greater (106.32/100 000; 95% CI: 100.63/100 000–112.25/100 000) than the pooled rate of the other developed countries combined (22.85/100 000; 95% CI: 9.74/100 000–53.63/100 000). Hypotensive reactions after RBC transfusion occurred less frequently, in 2 patients per 100 000 RBC units (RIH = 34.3%).
### Allergic reaction

| Country   | Years       | Rate/100 000 Units (95% CI)       |
|-----------|-------------|-----------------------------------|
| Australia | 2010-2011   | 4·12 (2·84, 5·79)                  |
| Canada    | 2012        | 5·17 (3·99, 6·60)                  |
| Finland   | 2007        | 10·69 (7·05, 15·55)                |
| France    | 2009        | 16·07 (14·49, 17·78)               |
| Germany   | 2010        | 2·11 (1·71, 2·58)                  |
| Ireland   | 2010        | 7·86 (5·92, 14·05)                 |
| Japan     | 2012        | 4·69 (4·00, 5·47)                  |
| Netherlands | 2012     | 7·19 (5·01, 10·00)                 |
| New Zealand | 2013   | 62·72 (48·51, 79·79)               |
| Norway    | 2010        | 19·30 (13·66, 26·49)               |
| Portugal  | 2012        | 26·33 (21·17, 32·36)               |
| Spain     | 2013        | 33·65 (31·10, 36·37)               |
| Sweden    | 2013        | 3·29 (1·84, 5·42)                  |
| Switzerland | 2013      | 9·66 (6·37, 14·00)                 |
| USA       | 2010-2012   | 53·61 (49·59, 57·87)               |

### Anaphylactic reaction

| Country   | Years       | Rate/100 000 Units (95% CI)       |
|-----------|-------------|-----------------------------------|
| Australia | 2010-2011   | 1·62 (0·86, 2·78)                  |
| Denmark   | 2009        | 0·00 (0·00, 1·11)                  |
| Finland   | 2007        | 0·40 (0·01, 2·21)                  |
| Japan     | 2012        | 1·96 (1·52, 2·48)                  |
| Netherlands | 2012     | 1·85 (0·85, 3·61)                  |
| Norway    | 2010        | 1·02 (0·12, 3·67)                  |
| Portugal  | 2012        | 0·29 (0·01, 1·63)                  |
| Sweden    | 2013        | 0·68 (0·14, 1·92)                  |

### Acute Transfusion Reaction

| Country   | Years       | Rate/100 000 Units (95% CI)       |
|-----------|-------------|-----------------------------------|
| UK        | 2013        | 8·91 (7·66, 10·30)                 |

### Acute Transfusion-related Pain

| Country   | Years       | Rate/100 000 Units (95% CI)       |
|-----------|-------------|-----------------------------------|
| Sweden    | 2013        | 1·10 (0·36, 2·56)                  |

### Febrile Non-Hemolytic Transfusion Reaction

| Country   | Years       | Rate/100 000 Units (95% CI)       |
|-----------|-------------|-----------------------------------|
| Australia | 2010-2011   | 21·23 (18·16, 24·68)              |
| Finland   | 2007        | 40·39 (32·03, 49·03)              |
| France    | 2009        | 54·88 (51·92, 57·96)              |
| Germany   | 2010        | 0·62 (0·41, 0·90)                 |
| Ireland   | 2010        | 25·71 (18·01, 35·59)              |
| Japan     | 2012        | 3·43 (2·84, 4·10)                 |
| Netherlands | 2012     | 147·93 (137·33, 159·13)           |
| New Zealand | 2013   | 167·25 (143·47, 185·85)           |
| Norway    | 2012        | 17·78 (12·38, 24·72)              |
| Portugal  | 2012        | 65·53 (57·23, 74·69)              |
| Sweden    | 2013        | 8·55 (6·08, 11·68)                |
| Switzerland | 2013      | 32·56 (26·21, 39·97)              |
| USA       | 2010-2012   | 106·32 (100·63, 112·25)           |

### Febrile, hypotensive reaction

| Country   | Years       | Rate/100 000 Units (95% CI)       |
|-----------|-------------|-----------------------------------|
| Spain     | 2013        | 48·27 (45·20, 51·50)              |

### Hypotensive reaction

| Country   | Years       | Rate/100 000 Units (95% CI)       |
|-----------|-------------|-----------------------------------|
| Canada    | 2012        | 4·94 (3·78, 6·33)                  |
| Finland   | 2007        | 0·40 (0·01, 2·21)                  |
| Ireland   | 2010        | 1·43 (0·17, 5·16)                  |
| Japan     | 2012        | 1·56 (1·17, 2·03)                  |
| New Zealand | 2013       | 0·95 (0·02, 5·29)                  |
| Norway    | 2010        | 0·51 (0·01, 2·83)                  |
| Portugal  | 2012        | 3·51 (1·81, 6·13)                  |
| Sweden    | 2013        | 1·10 (0·36, 2·56)                  |
| USA       | 2010-2012   | 6·12 (4·81, 7·67)                  |

© 2015 International Society of Blood Transfusion

*Vox Sanguinis* (2016) 110, 266–277
hypotensive reactions were combined with FNHTR, yielding a rate of 48 patients in 100,000 RBC units.

Acute transfusion-related pain was reported separately in the Swedish haemovigilance system, occurring in one patient per 100,000 RBC units (Fig. 2).

Rates of acute and delayed haemolytic transfusion reactions are shown in Fig. 3. Acute haemolytic transfusion reactions occurred in 1 patient per 100,000 RBC units administered (RIH = 8.3%), while a delayed haemolytic transfusion reaction occurred in approximately two patients per 100,000 RBC units (RIH = 57.0%). In Germany, Spain and the United Kingdom, both acute and delayed haemolytic transfusion reactions were combined, yielding a pooled rate of 1.4/100,000 units (RIH = 57.0%). Both Ireland and the USA tended to have delayed haemolytic transfusion reactions at a greater frequency than other countries, although the confidence intervals for Ireland were wide indicating fewer RBC units due to a smaller population. The rate of delayed haemolytic transfusion reactions in the USA was significantly greater (6.94/100,000; 95% CI: 5.54/100,000–8.58/100,000) than the pooled rate of the other developed countries combined (1.6/100,000; 95% CI: 0.9/100,000–2.8/100,000).

Respiratory reactions to RBC transfusion are shown in Fig. 4. Transfusion-associated dyspnoea was reported in two patients per 100,000 RBC units (RIH = 77.4%). New Zealand was an outlier in this category. TRALI associated with RBC units was quite low (Fig. 4), at a pooled rate of 0.35 per 100,000 RBC units (RIH = 73.2%).

TACO occurred in approximately three patients for each 100,000 RBC units transfused, although there was some variation in rates across countries (Fig. 5; RIH = 76.9%). Haemosiderosis was reported separately in France and Spain and occurred at a rate of 0.3 for every 100,000 units transfused (RIH = 99.6%).

The results for delayed serologic transfusion reactions are given in Fig. 6, showing heterogeneity across countries (RIH = 91.5%; rate = 24.6/100,000 units), with elevated rates in the Netherlands and Switzerland. Post-transfusion purpura occurred rarely, at a rate of 0.08 per 100,000 RBC units administered (Fig. 6; RIH = 0%). Other transfusion-related reactions, as shown in Fig. 6, varied by country and were not described in great detail in the country-specific annual reports.

Documented cases of transfusion-transmitted bacterial sepsis occurred rarely, approximately once in every million RBC units administered (Fig. 7; RIH = 57.8%). Table 1 displays the estimate residual risk of viral transmission due to RBC transfusion. Rates were very low. HIV and hepatitis B and C viruses were most often transmitted due to RBC transfusion. Rates were very low. HIV and hepatitis B and C viruses were most often transmitted due to RBC transfusion.

---

**Table 1**

| Country | Years       | Rate/100,000 Units (95% CI) |
|---------|-------------|-----------------------------|
| **Acute Hemolytic Transfusion Reaction** |
| Australia | 2010-2011 | 0.13 (0.00, 0.70) |
| Canada     | 2012     | 1.19 (0.67, 1.97) |
| Finland    | 2007     | 1.19 (0.25, 3.47) |
| Ireland    | 2010     | 2.86 (0.78, 7.31) |
| Netherlands| 2012     | 1.23 (0.45, 2.68) |
| New Zealand| 2013     | 0.95 (0.02, 5.29) |
| Norway     | 2010     | 2.03 (0.55, 5.20) |
| Portugal   | 2012     | 2.34 (1.01, 4.61) |
| Sweden     | 2013     | 0.44 (0.05, 1.58) |
| USA        | 2010-2012| 1.55 (0.93, 2.42) |
| Summary Estimate |        | 1.14 (0.74, 1.75) |
| **Delayed Hemolytic Transfusion Reaction** |
| Australia  | 2010-2011| 0.75 (0.28, 1.63) |
| Canada     | 2012     | 3.03 (2.14, 4.15) |
| Denmark    | 2009     | 1.20 (0.33, 3.08) |
| Finland    | 2007     | 1.58 (0.43, 4.06) |
| Ireland    | 2010     | 7.86 (3.92, 14.05) |
| Netherlands| 2012     | 1.64 (0.71, 3.24) |
| New Zealand| 2013     | 1.90 (0.23, 8.87) |
| Norway     | 2010     | 1.52 (0.31, 4.45) |
| Sweden     | 2013     | 0.44 (0.05, 1.58) |
| USA        | 2010-2012| 6.94 (5.54, 8.58) |
| Summary Estimate |        | 1.91 (1.08, 3.39) |
| **Hemolytic Transfusion Reaction** |
| Germany    | 2010     | 0.36 (0.20, 0.58) |
| Spain      | 2013     | 3.52 (2.65, 4.40) |
| UK         | 2013     | 2.35 (1.73, 3.11) |
| Summary Estimate |        | 1.44 (0.47, 4.42) |

---

Fig. 3 Rates of haemolytic reactions in haemovigilance reports, by Country.
other viruses (cytomegalovirus, Epstein–Barr, etc.) were available from only a few countries.

Rates of adverse reactions in the USA, as generated through haemovigilance, were compared to documented rates obtained through active surveillance. Published frequency rates of TACO are shown in Table 2 [26–32]. When units were used as the denominator, the pooled rate of TACO was 368 per 100 000 units or one in every 271
units from active surveillance. This compares with one in 10942 units from passive surveillance through the haemovigilance programme in the USA.

In general, rates of FNHTR were lower in leucoreduced versus non-leucoreduced products within the same population (Table 3) [33–44]. With prospective surveillance, the pooled rate of FNHTR was 1191/100000 units or one in every 84 units; this compares with one case in 3885 RBC units from haemovigilance. The rates tended to be greater in children than adults; one in 20 children who received a transfusion developed FNHTR (all component types combined). FNHTR rates also appeared higher in patients with cancer.

**Discussion**

Haemovigilance systems in developed nations report low rates of adverse events after RBC transfusion. For
Table 1 Risk of transfusion-transmitted viruses in haemovigilance reports, by Country

| Virus                               | Country     | Years       | Rate               |
|-------------------------------------|-------------|-------------|--------------------|
| Cytomegalovirus                     | France      | 2009        | 1 in 1.5 million   |
|                                     | The Netherlands | 2012       | <1 in 620 000      |
|                                     | Norway      | 2004-2010   | 1 in 1.4 million   |
| Epstein–Barr Virus                  | The Netherlands | 2012       | <1 in 620 000      |
| Hepatitis A Virus                   | France      | 2009        | <1 in 3 million    |
|                                     | The Netherlands | 2012       | <1 in 620 000      |
|                                     | Norway      | 2004-2010   | 1 in 1.4 million   |
| Hepatitis B Virus                   | Australia   | 2012-2013   | 1 in 720 000       |
|                                     | Canada      | 2006-2009   | 1 in 1.7 million   |
|                                     | Denmark     | 2009        | 1 in 270 000       |
|                                     | Finland     | 2007        | <1 in 450 000      |
|                                     | France      | 2009        | <1 in 3 million    |
|                                     | Germany     | 2010        | 1 in 6.1 million   |
|                                     | Ireland     | 2010-2011   | <1 in 190 000      |
|                                     | Japan       | 2012        | 1 in 880 000       |
|                                     | The Netherlands | 2012       | <1 in 620 000      |
|                                     | New Zealand | 2013        | 1 in 680 000       |
|                                     | Spain       | 2013        | 1 in 1.9 million   |
|                                     | Switzerland | 2013        | 1 in 400 000       |
|                                     | UK          | 2013        | 1 in 2.8 million   |
|                                     | USA         | 2006-2008   | 1 in 300 000       |
| Hepatitis C Virus                   | Australia   | 2012-2013   | <1 in 1 million    |
|                                     | Canada      | 2006-2009   | 1 in 6.7 million   |
|                                     | Denmark     | 2009        | <1 in 540 000      |
|                                     | Finland     | 2007        | <1 in 450 000      |
|                                     | France      | 2009        | <1 in 3 million    |
|                                     | Germany     | 2010        | <1 in 6.1 million  |
|                                     | Ireland     | 2010-2011   | <1 in 190 000      |
|                                     | The Netherlands | 2012       | <1 in 620 000      |
|                                     | Sweden      | 2013        | <1 in 460 000      |
|                                     | Switzerland | 2013        | 1 in 6.7 million   |
|                                     | UK          | 2013        | <1 in 2.8 million  |
|                                     | USA         | 2007-2008   | 1 in 1.1 million   |
| Hepatitis E Virus                   | France      | 2009        | <1 in 3 million    |
|                                     | Japan       | 2012        | 1 in 1.3 million   |
|                                     | UK          | 2013        | 1 in 2.8 million   |
| Human Immunodeficiency Virus        | Australia   | 2012-2013   | <1 in 1 million    |
|                                     | Canada      | 2006-2009   | 1 in 6.7 million   |
|                                     | Denmark     | 2009        | <1 in 540 000      |
|                                     | Finland     | 2007        | <1 in 450 000      |
|                                     | France      | 2009        | <1 in 3 million    |
|                                     | Germany     | 2010        | 1 in 6.1 million   |
|                                     | Ireland     | 2010-2011   | <1 in 190 000      |
|                                     | The Netherlands | 2012       | <1 in 620 000      |
|                                     | New Zealand | 2013        | <1 in 140 000      |
|                                     | Switzerland | 2013        | 1 in 4.1 million   |
|                                     | UK          | 2013        | <1 in 2.8 million  |
|                                     | USA         | 2007-2008   | 1 in 1.5 million   |
| Human T-Lymphotropic Virus          | Australia   | 2012-2013   | <1 in 1 million    |
|                                     | The Netherlands | 2012       | <1 in 620 000      |
|                                     | USA         | 2000-2001   | <1 in 2.1 million  |
| Parvovirus B19                      | France      | 2009        | 1 in 3 million     |

Table 1 (Continued)

| Virus                               | Country     | Years       | Rate               |
|-------------------------------------|-------------|-------------|--------------------|
| Varicella Zoster Virus              | Norway      | 2004-2010   | 1 in 1.4 million   |

overall, TACO occurred at a rate of three cases per 100 000 units when pooled from haemovigilance reports, with the incidence of TACO in the USA alone being one in 10942 units. However, based on active surveillance studies from the USA, 0.6% to 8% of patients receiving RBC transfusions develop TACO. This disparity between active and passive surveillance rates may stem from insufficient reporting of reactions to haemovigilance systems. For example, researchers from the Mayo Clinic noted that there were 176 cases of TACO in their investigation but only three were in the transfusion database that housed adverse reactions – and even then, these three cases were not labelled as TACO [31].

Given the more comprehensive monitoring of fever after RBC transfusion, the variability of rates of FNHTR across countries may be a reflection of dissimilarities in patient populations, differential use of pretransfusion antipyretic medications or the preparation of RBC units. Of note, the USA has not adopted universal leucoreduction (70-5% RBC units leucoreduced in 2011) [46] and FNHTR has been reported more frequently in patients receiving non-leucoreduced products [33, 39, 41, 42, 47]. FNHTR rates in the USA are higher than the pooled FNHTR rates in other developed countries and the use of non-leucoreduced products could partially account for these findings.

The variability in rates of allergic reactions across nations may stem from differences in case definitions. In Australia, for example, a severe allergic reaction would be recorded if rash, allergic dyspnoea, angioedema, generalized pruritis or urticaria occurred within 24 h of the transfusion [7]. In the USA, a severe allergic reaction...

\[ \text{Risk of transfusion-transmitted viruses} \]

anaphylaxis, hypotension and purpura, the rates were quite consistent across countries. Rates of some reactions, however, were notably elevated in particular countries. Rates of allergic reactions were higher in the USA and New Zealand; rates of FNHTR were elevated in the USA, the Netherlands and New Zealand; and TACO was more commonly reported in Canada, France, Ireland, the Netherlands and the USA. New Zealand reported a greater rate of transfusion-associated dyspnoea in 2013. However, in a recent report, more than half of the dyspnoea cases were reclassified when additional information was retrieved [many being reclassified as TACO] [45].

Overall, TACO occurred at a rate of three cases per 100 000 units when pooled from haemovigilance reports, with the incidence of TACO in the USA alone being one in 10942 units. However, based on active surveillance studies from the USA, 0.6% to 8% of patients receiving RBC transfusions develop TACO. This disparity between active and passive surveillance rates may stem from insufficient reporting of reactions to haemovigilance systems. For example, researchers from the Mayo Clinic noted that there were 176 cases of TACO in their investigation but only three were in the transfusion database that housed adverse reactions – and even then, these three cases were not labelled as TACO [31].

Given the more comprehensive monitoring of fever after RBC transfusion, the variability of rates of FNHTR across countries may be a reflection of dissimilarities in patient populations, differential use of pretransfusion antipyretic medications or the preparation of RBC units. Of note, the USA has not adopted universal leucoreduction (70-5% RBC units leucoreduced in 2011) [46] and FNHTR has been reported more frequently in patients receiving non-leucoreduced products [33, 39, 41, 42, 47]. FNHTR rates in the USA are higher than the pooled FNHTR rates in other developed countries and the use of non-leucoreduced products could partially account for these findings.

The variability in rates of allergic reactions across nations may stem from differences in case definitions. In Australia, for example, a severe allergic reaction would be recorded if rash, allergic dyspnoea, angioedema, generalized pruritis or urticaria occurred within 24 h of the transfusion [7]. In the USA, a severe allergic reaction...
would be recorded if two or more symptoms (conjunctival oedema; oedema of lips, tongue and uvula; erythema and oedema of the periorbital area; generalized flushing; hypotension; localized angioedema; maculopapular rash; pruritus; respiratory distress or bronchospasm; urticaria) occurred during or within 4 h of the cessation of transfusion [48]. Moreover, in some countries such as New Zealand, both non-severe and severe allergic reactions are reported [17] (perhaps reflecting their higher rates as shown in Fig. 1) while in the USA, reporting of non-severe allergic reactions is not required [48]. Other reasons for differences in rates may be variations in hospital-specific reporting practices and the mandatory/voluntary nature of the reporting.

For events such as delayed serologic transfusion reaction and delayed haemolytic transfusion reaction, the definition hinges on laboratory testing and not symptoms. Rate differences may be a reflection of the resources afforded for testing of alloantibodies and the feasibility of longitudinal observation. Information regarding follow-up procedures or standardization of procedures would enhance the interpretability of rates. Alternatively, haemovigilance programmes may reconsider the usefulness of expending resources to capture such data when the likelihood of consistent, meaningful information is low. Perhaps periodic systematic testing in high users of transfusion would be more appropriate such as in patients with sickle-cell disease or cancer, or in participants of cardiovascular disease registries.

Results from this investigation indicate that the residual risks from currently tested infectious agents are very low and, in many instances, could be considered negligible. However, it is the potential risks from other infectious agents (not yet tested) which is more pertinent at this time. These include vCJD, hepatitis E virus, dengue viruses, Chikungunya virus, Babesia spp., West Nile virus and Middle East respiratory syndrome coronavirus – although the list of potential threats includes approximately 70 such agents [49]. For example, in the USA, transfusion-transmitted babesiosis has been documented in more than 200 instances and is associated with the greatest case fatality rate of transfusion-related infections [50].

Haemovigilance for transfusion-transmitted infection is meant to capture pathogen transmission from donor to recipient. The requirements include the demonstration of

| Author, year | Source | Type of study | Incidence | Incidence Components | Year |
|--------------|--------|---------------|-----------|----------------------|------|
| Popovsky [26], 1996 | 5 Massachusetts hospitals, total hip or knee replacements | Retrospective cohort | 1% of patients | 1 in 95 patients | All 1992–1993 |
| Bierbaum [27], 1999 | 235 hospitals, total hip or knee arthroplasty | Prospective cohort | 8% of patients | 1 in 12 patients | All 1996–1997 |
| Rana [28], 2006 | Mayo Clinic, intensive care units | Prospective cohort | 1–85% of patients | 1 in 54 patients | All 2003 |
| Li [29], 2011 | Mayo Clinic, medical intensive care unit | Prospective cohort | 5–7% of patients | 1 in 18 patients | All 2 years, before 2007 |
| Andrzejewski [30], 2012 | Hospital in Massachusetts, all ages | Retrospective cohort | 0–6% of patients | 1 in 166 patients | RBCs 2005–2008 |
| Clifford [31], 2015 | Mayo Clinic, adults, non-cardiac surgery | Retrospective cohort | 5–5% of patients | 1 in 18 patients | All 2004 |
| | | | 3% of patients | 1 in 33 patients | All 2011 |

**Frequency per unit:**

| Author, year | Source | Type of study | Incidence | Incidence Components | Year |
|--------------|--------|---------------|-----------|----------------------|------|
| Rana [28], 2006 | Mayo Clinic, intensive care units | Prospective cohort | 281/100 000 units | 1 in 356 units | All 2003 |
| Andrzejewski [30], 2012 | Hospital in Massachusetts, all ages | Retrospective cohort | 189/100 000 units | 1 in 530 units | RBCs 2005–2008 |
| Harvey [6], 2014 | National Healthcare Safety Network, 77 facilities | Voluntary haemovigilance | 9/100 000 units | 1 in 10942 units | All 2010–2012 |
| Clifford [31], 2015 | Mayo Clinic, adults, non-cardiac surgery | Retrospective cohort | 4000/100 000 units | 1 in 25 units | RBCs 2004 |
| | | | 1087/100 000 units | 1 in 92 units | RBCs 2011 |

**Frequency per hospital stay:**

| Author, year | Source | Type of study | Incidence | Incidence Components | Year |
|--------------|--------|---------------|-----------|----------------------|------|
| Menis [32], 2014 | Medicare administrative database | Retrospective | 0.06% of stays | 1 in 1602 stays | All 2011 |
Table 3 Incidence of febrile non-haemolytic transfusion reaction in the United States

| Author, year | Source | Type of study | Incidence | Incidence Components | Year |
|--------------|--------|---------------|-----------|----------------------|------|
| Frequency per patient |          |               |           |                      |      |
| Paglino [33], 2004 | Yale-New Haven Hospital, Connecticut, all ages | Retrospective cohort | 1 33% of patients | 1 in 75 patients | 25% leucoreduced RBCs | 1995–1998 |
| Sanders [34], 2005 | St. Jude Children's Research Hospital | Retrospective cohort | 0 79% of patients | 1 in 127 patients | 99% leucoreduced RBCs | 2000–2002 |
| Kennedy [35], 2008 | Wake Forest University Comprehensive Cancer Center | Prospective active surveillance | 8 70% of patients | 1 in 11 patients | RBCs and PLTs, leucoreduced | 1993–1997 |
| Frequency per unit |          |               |           |                      |      |
| Menitove [36], 1982 | 33 Hospitals in South-eastern Wisconsin, all ages | Retrospective cohort | 478/100 000 units | 1 in 209 units | RBCs and whole blood | 1980 |
| Dzieczkowski [37], 1995 | Dana-Farber Cancer Institute, Boston, Massachusetts | Prospective cohort | 340/100 000 units | 1 in 294 units | 25% leucoreduced RBCs | 1993 |
| Federowicz [38], 1996 | Dana-Farber Cancer Institute, Boston, Massachusetts | Prospective cohort | 79/100 000 units | 1 in 592 units | Non-leucoreduced RBCs | Before 1995 |
| Uhman [39], 2001 | Barnes-Jewish Hospital, St. Louis, Missouri | Retrospective cohort | 2147/100 000 units | 1 in 47 units | RBCs, leucoreduced after storage | 1993 |
| Domini [40], 2003 | Cleveland Clinic, Ohio, all ages | Retrospective cohort | 106/100 000 units | 1 in 941 units | Leucoreduced RBCs | 1999 |
| Paglino [33], 2004 | Yale-New Haven Hospital, Connecticut, all ages | Retrospective cohort | 186/100 000 units | 1 in 271 units | Leucoreduced RBCs | 2000 |
| King [41], 2004 | The Johns Hopkins Hospital, all ages | Retrospective cohort | 162/100 000 units | 1 in 538 units | RBCs | 2001 |
| Eziedie [42], 2004 | State University of New York, Syracuse, adults, nonsurgical | Retrospective cohort | 123/100 000 units | 1 in 538 units | Leucoreduced RBCs | 2001–2002 |
| Sanders [34], 2005 | St. Jude Children's Research Hospital | Retrospective cohort | 184/100 000 units | 1 in 545 units | Leucoreduced RBCs | 2000 |
| Kennedy [35], 2008 | Wake Forest University Comprehensive Cancer Center | Prospective active surveillance | 124/100 000 units | 1 in 809 units | Leucoreduced RBCs | 2002 |
| Frequency per hospital stay |          |               |           |                      |      |
| Menis [44], 2015 | Medicare administrative database | Retrospective | 0 07% of stays | 1 in 1419 stays | RBCs | 2011–2012 |

© 2015 International Society of Blood Transfusion

Vox Sanguinis (2016) 110, 266–277
the pathogen in the transfused component, or in the donor at the time of donation, or in an additional component from the same donation, or in an additional recipient of a component from the same donation [48]. Also required is documentation that there are no other potential exposures to the pathogen that could be identified in the recipient and either evidence that the recipient was not infected with the pathogen prior to transfusion or evidence that the pathogen strains are related by molecular or extended phenotypic comparison testing [48]. This is a difficult target to reach when such in-depth testing is not usually conducted with each transfusion. Therefore, the pooled rate of transfusion-transmitted bacterial sepsis is a difficult target to reach when such in-depth testing is not usually conducted with each transfusion. Therefore, the pooled rate of transfusion-transmitted bacterial sepsis was very low (0.83/1 million RBC units). There are few published reports of prospective surveillance for comparison purposes. Barrett and colleagues [51] found a bacterial contamination rate of 3.2/100 000 RBC units, while Dzieczkowski and colleagues [37] reported this rate to be 14.1/100 000 RBC units. In a more recent report from Denmark, 35% of RBC units contained viable bacteria which were obtained from donors 50 years of age or older [52].

There are avenues for improvement in existing haemovigilance systems. The addition of active surveillance components may enhance reporting. Expansion of electronic medical records to incorporate more information regarding blood administration may augment comprehensiveness. Adjunct programming routines could be enacted to capture pre- and post-transfusion temperatures so that detection of FNHTR could be improved. Likewise, electronic capture of pre- and post-transfusion blood pressures could assist the detection of hypotensive reactions. Some have already merged records from transfusion and apheresis medicine with the main electronic medical record [53–55]. The SCANDAT2 is a successful example of linked donor and recipient health information in Sweden and Denmark [55]. In addition, international networks (e.g. International Haemovigilance Network [56], Global Vigilance and Surveillance Database for Medical Products of Human Origin [57], World Health Organization Global Database on Blood Safety [58]) provide opportunities for surveillance and the improvement of blood safety.

National haemovigilance programmes afford an important aspect of patient safety. Such systems generally capture serious transfusion reactions but, with improvement, could generate more comprehensive information. Cross-country comparisons can provide the basis for discovery and continuous process improvement.

Acknowledgements

All authors contributed to the design, analysis or data interpretation; made critical revisions of the manuscript; and approved the submitted final version.

References

1 Salmi LR, Hervé P: L’organisation de l’hémovigilance en France. TCB 1994; 3:252–256
2 Tadokoro K: The new Japanese blood law: its impact on blood safety and usage. Dev Biol (Basel) 2007; 127:161–168
3 Folléa G, Aranko K: European Blood Alliance: The revision of the European blood directives: a major challenge for transfusion medicine. Transfus Clin Biol 2015; S1246-7820:00032–00034
4 Bolton-Maggs P, Working Expert Group & Writing Group, Royal College of Pathologists: Annual SHOT Report: Serious Hazards of Transfusion (SHOT) 2013. Available at: http://www.shotuk.org/wp-content/uploads/74280-SHOT-2014-Annual-Report-V12-WEB.pdf (accessed July 9th, 2015)
5 TRIP Hemovigilance and biovigilance office: TRIP annual report: Hemovigilance extended version, 2012. Available at: http://www.tripnet.nl/pages/en/documents/TRIP2012Hemovigilantie_5/12646/ENGELS4.pdf (accessed July 9th, 2015)
6 Harvey AR, Basavaraju SV, Chung KW, et al.: Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012. Transfusion 2015; 55:709–718
7 National Blood Authority: Australian Haemovigilance Report: data for 2009-10 and 2010-11. Available at: http://www.blood.gov.au/haemovigilance-reporing (accessed July 9th, 2015)
8 Public Health Agency of Canada: Transfusion transmitted injuries surveillance system (TTISS): summary results for 2006-2012. Available at: http://www.phac-aspc.gc.ca/hcai-iamss/ttiss-sst/index-eng.php (accessed July 9th, 2015)
9 Taaning EM, Sorensen B, Riisom K: Danish Registration of Transfusion Risk (DART) hemovigilance report for 2009. Available at: http://dski.dk/files/DART_2009.pdf (accessed July 9th, 2015)
10 Finnish Red Cross Blood Service: Adverse transfusion events in Finland 2007. Available at: http://www.hemovigilans.se/downloads/BSO_2007.pdf (accessed July 9th, 2015)
11 French Agency for the Safety of Health Products: Annual Haemovigilance report 2009. Available at: http://ansm.sante.fr/var/ansm_site/storage/original/application/bb2a6b52bd0935954bd985d63b8e0e734.pdf (accessed July 9th, 2015)
12 Lohmann A, Halbauer J, Witzenhausen C, et al.: Haemovigilance report of the Paul-Ehrlich Institute: Assessment of the reports of serious adverse transfusion reactions, 2010. Available at: http://www.pei.de/SharedDocs/Downloads/vigilanz/haemovigilanz/publikationen/haemovigilance-report-2010.pdf?__blob=publicationFile&v=3 (accessed July 9th, 2015)
13 National Haemovigilance Office: NHO Report 2010/2011, Ireland. Available at: http://www.giveblood.ie/Clinical_Services/Haemovigilance/Publications/NHO-Annual-Report-2011.pdf (accessed July 9th, 2015)

14 Japanese Red Cross Society: Non-hemolytic adverse transfusion reactions reported to JRC Blood Centers, 2012. Available at: http://www.jrc.or.jp/eng/ (accessed July 9th, 2015)

15 Japanese Red Cross Society: Transfusion-related acute lung injury, 2012. Available at: http://www.jrc.or.jp/eng/ (accessed July 9th, 2015)

16 Japanese Red Cross Society: Infectious cases of probably related to transfused blood components, 2012. Available at: http://www.jrc.or.jp/eng/ (accessed July 9th, 2015)

17 Badami K, Buhrkuhl D, Sadani D, et al.: National Haemovigilance Group. National haemovigilance programme, Annual report, 2013. Available at: http://www.nzblood.co.nz/assets/Haemovigilance/NHO-Annual-Report-2011.pdf (accessed July 9th, 2015)

18 Norwegian Knowledge Centre for the Health Services: Monitoring of Blood: haemovigilance report, 2010. Available at: http://www.kunnskapssenteret.no/en/publications/surveillance-of-blood-in-norway-2010.troll.adverse-outcomes-of transfusion (accessed July 9th, 2015)

19 De Sousa G, Miranda I, Pires I, et al.: Report of the Portuguese Haemovigilance System, 2012. Available at: http://www.hemovigilancia.net/docs/re latorio_sphv_2012.pdf (accessed July 9th, 2015)

20 De Sousa G, Miranda I, Pires I, et al.: Activity report of the services of blood and transfusion medicine, 2012. Available at: http://www.hemovigilancia.net/docs/relatorio_atividade_ss_smt_2012.pdf (accessed July 9th, 2015)

21 Hemovigilance Unit, Public Health, Quality and Innovation: Hemovigilance, Spain, 2013. Available at: http://www.msssi.gob.es/profesionales/saludPublica/medicinaTransfusional/hemovigilancia/docs/Informe2013.pdf (accessed July 9th, 2015)

22 Sävwenberg J, Pafth M: Report from the BIS - Blood Monitoring in Sweden. Hemovigilance in Sweden 2011-2013. Available at: http://www.kitm.se/swi/wp-content/uploads/2014/10/Hemovigilance-i-Sverige-2011-2013.pdf (accessed July 9th, 2015)

23 Jutzi M, Amsler L. Swissmedic Haemovigilance Annual report, Switzerland, 2013. Available at: https://www.swissmedic.ch/marktue berwachung/00138/00188/index.html?lang=en&ndownload=NHzLzp7eg7tlnq6d0NTU042Z6u1adl1iZv4Zq2pzn02Yu q2Z6gpJCDdoN5e2ym162epYbg2c_JKbNoKSm6A– (accessed July 9th, 2015)

24 Schreiber G, Busch MP, Kleinman SH, et al.: The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334:1685–1690

25 Trikalinos TA, Trow P, Schmid CH: Simulation-Based Comparison of Methods for Meta-Analysis of Proportions and Rates. AHRQ Publication No. 13(14)-EHC084-EE. November 2013. Available at: http://www.ncbi.nlm.nih.gov/books/NBK179162/ (accessed July 9th, 2015)

26 Popovska MA, Aydet AM, Andrzewski C Jr: Transfusion-associated circulatory overload in orthopedic surgery patients: a multi-institutional study. Immunohematology 1996; 12:87–89

27 Bierbaum BE, Callaghan JJ, Galante JO, et al.: An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999; 81:2–10

28 Rana R, Fernández-Pérez ER, Khan SA, et al.: Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion 2006; 46:1478–1483

29 Li G, Rachmale S, Kojicic M, et al.: Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients. Transfusion 2011; 51:338–343

30 Andrzewski C Jr, Popovska MA, Stec TC, et al.: Hemotherapy bedside biovigilance involving vital sign values and characteristics of patients with suspected transfusion reactions associated with fluid challenges: can some cases of transfusion-associated circulatory overload have proinflammatory aspects? Transfusion 2012; 52:2310–2320

31 Clifford L, Jia Q, Yadav H, et al.: Characterizing the epidemiology of perioperative transfusion-associated circulatory overload. Anesthesiology 2015; 122:21–28

32 Menis M, Anderson SA, Forshee RA, et al.: Transfusion-associated circulatory overload (TACO) and potential risk factors among the inpatient US elderly as recorded in Medicare administrative databases during 2011. Vox Sang 2014; 106:144–152

33 Paglino JC, Pomper GJ, Fisch GS, et al.: Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion 2004; 44:16–24

34 Sanders R, Maddirala SD, Geiger TL, et al.: Pemedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children. Br J Haematol 2005; 130:781–787

35 Kennedy LD, Case LD, Hurd DD, et al.: A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretransfusion medication versus placebo for the prevention of transfusion reactions. Transfusion 2008; 48:2285–2291

36 Menitove JE, McEllogint MC, Aster RH: Febrile transfusion reaction: what blood component should be given next? Vox Sang 1982; 42:318–321

37 Dzieczkowski JS, Barrett BB, Nester D, et al.: Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components. Transfusion 1995; 35:20–25

38 Fedorowicz I, Barrett BB, Andersen JW, et al.: Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage. Transfusion 1996; 36:21–28

39 Uhmann EJ, Isgriggs E, Wall hernfuchelt M, et al.: Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion 2001; 41:997–1000

40 Domen RE, Hoeltge GA: Allergic transfusion reactions: an evaluation of 273 consecutive reactions. Arch Pathol Lab Med 2003; 127:316–320

41 King KE, Shirey RS, Thoman SK, et al.: Universal leukoreduction
decreases the incidence of febrile non-hemolytic transfusion reactions to RBCs. Transfusion 2004; 44:25–29
42 Eziediegwu CN, Lauenstein KJ, Rosales LG, et al.: Febrile non-hemolytic transfusion reactions. Management by premedication and cost implications in adult patients. Arch Pathol Lab Med 2004; 128:991–995
43 Oakley FD, Woods M, Arnold S, et al.: Transfusion reactions in pediatric compared with adult patients: a look at rate, reaction type, and associated products. Transfusion 2015; 55:563–570
44 Menis M, Forshee RA, Anderson SA, et al.: Febrile non-haemolytic transfusion reaction occurrence and potential risk factors among the U.S. elderly transfused in the inpatient setting, as recorded in Medicare databases during 2011-2012. Vox Sang 2015; 108:251–261
45 Badami KG, Joliffe E, Stephens M: Transfusion-associated dyspnøea - shadow or substance? Vox Sang 2015; 109:197–200.
46 Whitaker BI, Hinkins S: The 2011 National Blood Collection and Utilization Survey Report. US Department of Health and Human Services, 2011.
47 Blumberg N, Heal JM, Gettings KF, et al.: An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions. Transfusion 2010; 50:2738–2744
48 Centers for Disease Control and Prevention: National Healthcare Safety Network, Biovigilance Component, Hemovigilance Module, Surveillance Protocol, v2.1.3, 2014. Available at: http://www.cdc.gov/nhsn/PDFs/Biovigilance/BV-HV-protocol-current.pdf [accessed July 9th, 2015]
49 Stramer SL: Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections. ISBT Sci Ser 2014; 9:30–36
50 Blood Products Advisory Committee, Food and Drug Administration: Strategies for implementation of antibody and nucleic acid-based testing for Babesia microti in blood donors, 2015: Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/bloodproductsadvisorycommittee/ucm446274.pdf [accessed July 9th, 2015]
51 Barrett BB, Anderson JW, Anderson KC: Strategies for the avoidance of bacterial contamination of blood components. Transfusion 1993; 133:228–233
52 Damgaard C, Magnussen K, Enevold C, et al.: Viable bacteria associated with red blood cells and plasma in freshly drawn blood donations. PLoS ONE 2015; 10:e0120826
53 Levy R, Pantanowitz L, Cloutier D, et al.: Development of electronic medical record charting for hospital-based transfusion and apheresis medicine services: Early adoption perspectives. J Pathol Inform 2010; 1. pii:8
54 Clifford L, Singh A, Wilson GA, et al.: Electronic health record surveillance algorithms facilitate the detection of transfusion-related pulmonary complications. Transfusion 2013; 53:1205–1216
55 Edgren G, Rostgaard K, Vasan SK, et al.: The new Scandinavian Donations and Transfusions database (SCANDAT2): a blood safety resource with added versatility. Transfusion 2015; 55:1600–1606
56 International Haemovigilance Network. ISTARE. Available at: http://www.ihn-org.com/haemovigilance-databases/istare-2/ (accessed September 29th, 2015)
57 The Global Vigilance and Surveillance Database for Medical Products of Human Origin. NOTIFY Library. Available at: http://www.notifylibrary.org/ (accessed September 29th, 2015)
58 World Health Organization. Global Database on Blood Safety. Available at: http://www.who.int/bloodsafety/global_database/en/ (accessed September 29th, 2015)